Pramipexole (Prami)

FDA Approved

Dopamine Agonist | Prolactin Management Alternative

Weight: 211.33 Da

Half-life: ~8 hours

5 studies

2010 latest

FDA Approved

Dose 0.25-0.5mg daily at bedtime (start at 0.125mg and titrate slowly)

Frequency Once daily at bedtime

Cycle Duration of 19-nor compound use; taper off when discontinuing

Storage Room temperature (20-25C), protected from light and moisture

Accumulation Plotter

Community Research

Join others researching Pramipexole — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings

Discussion Questions & experiences

Submit Your Findings Contribute your research data

Pramipexole is a non-ergoline dopamine agonist with preferential affinity for the D3 dopamine receptor subtype. It is FDA-approved under the brand names Mirapex and Mirapexin for the treatment of Parkinson's disease and restless legs syndrome (RLS). In the bodybuilding and performance enhancement context, pramipexole serves as an alternative to cabergoline for managing prolactin elevation caused by 19-nor anabolic steroids such as nandrolone (Deca-Durabolin, NPP) and trenbolone. While less potent than cabergoline at suppressing prolactin, pramipexole is typically cheaper and more readily available, making it a practical option when cabergoline is difficult to source. Its shorter half-life of approximately 8 hours necessitates daily dosing (usually at bedtime), and it must be titrated slowly from a low starting dose to minimize side effects -- particularly nausea, which is common during initiation. Pramipexole is generally considered a second-choice prolactin management agent behind cabergoline due to its lower potency, shorter duration, and less favorable side effect profile at the doses sometimes needed for adequate prolactin suppression.

Mechanism of Action

Pramipexole exerts its prolactin-suppressing effects by acting as a full agonist at dopamine D2 and D3 receptors, with a marked preference for the D3 subtype. In the anterior pituitary, prolactin secretion by lactotroph cells is tonically inhibited by hypothalamic dopamine acting on D2 receptors. Pramipexole stimulates these D2 receptors to suppress prolactin gene transcription, synthesis, and release. Its preferential D3 activity also contributes to its clinical effects in Parkinson's disease and may account for some of its neuropsychiatric side effects, particularly impulse control disorders, which are mediated through mesolimbic D3 signaling pathways. In the context of 19-nor steroid use, nandrolone and trenbolone elevate prolactin through progestogenic activity at the pituitary, and pramipexole counteracts this by restoring dopaminergic inhibition. However, because pramipexole has lower D2 affinity and a much shorter half-life than cabergoline, higher relative doses and more frequent administration are needed to achieve comparable prolactin suppression.

01 Suppresses prolactin elevation caused by 19-nor anabolic steroids

02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline

03 Generally cheaper and more widely available than cabergoline

04 FDA-approved with a well-characterized safety and pharmacokinetic profile

05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles

06 Viable alternative when cabergoline cannot be sourced

Molecular Data

Molecular Weight

211.33 Da

Type

Non-ergoline dopamine D3 receptor agonist

Peak 0.0 mcg

Trough 0.0 mcg

SS Peak 0.0 mcg

SS Trough 0.0 mcg

Research Indications

19-Nor Compound Support

Prolactin Management on Nandrolone effective

Nandrolone (Deca-Durabolin and NPP) elevates prolactin through progestogenic activity. Pramipexole can be used as an alternative to cabergoline for managing prolactin-related side effects including sexual dysfunction and progesterone-mediated gynecomastia, though it is less potent and requires daily dosing.

Prolactin Management on Trenbolone effective

Trenbolone's strong progestogenic activity can elevate prolactin substantially. Pramipexole provides a functional alternative for prolactin control during trenbolone cycles, though users with significant prolactin elevation may find cabergoline more reliable.

Medical Applications

Parkinson's Disease most effective

FDA-approved for the treatment of signs and symptoms of idiopathic Parkinson's disease, both as monotherapy and as adjunct to levodopa. Pramipexole is effective at all stages of the disease and is particularly useful for managing motor symptoms in early Parkinson's.

Restless Legs Syndrome (RLS) most effective

FDA-approved for the treatment of moderate-to-severe primary restless legs syndrome. Low doses taken before bedtime significantly reduce RLS symptoms and improve sleep quality.

Dosing Protocols

Pramipexole is administered orally as a tablet, available in immediate-release and extended-release formulations. For prolactin management in bodybuilding contexts, the immediate-release tablet is standard. Oral bioavailability is greater than 90%, and absorption is not significantly affected by food. The relatively short half-life of approximately 8 hours requires daily dosing, typically taken at bedtime to minimize daytime drowsiness and nausea. Dosing must be titrated upward slowly from 0.125mg to the target dose over 1-2 weeks to reduce gastrointestinal and CNS side effects.

Goal	Dose	Frequency	Route
Prolactin management during 19-nor cycle (starting dose)	0.125mg	Once daily at bedtime	Oral
Prolactin management during 19-nor cycle (standard dose)	0.25mg	Once daily at bedtime	Oral
Prolactin management during 19-nor cycle (higher dose if needed)	0.5mg	Once daily at bedtime	Oral
Restless Legs Syndrome (medical)	0.125-0.5mg	Once daily, 2-3 hours before bedtime	Oral

Interactions

Nandrolone (Deca-Durabolin / NPP)

The primary use case for pramipexole in performance enhancement. Nandrolone elevates prolactin through progestogenic activity, causing sexual dysfunction and potential gynecomastia. Pramipexole counteracts this prolactin elevation, though it is less potent than cabergoline and requires daily dosing. Adequate for mild to moderate prolactin elevation in most users.

synergistic

Trenbolone

Trenbolone's potent progestogenic activity can cause significant prolactin elevation. Pramipexole provides functional prolactin control during trenbolone cycles, though users experiencing substantial prolactin-driven symptoms may require the greater potency of cabergoline.

synergistic

Cabergoline

Do not combine pramipexole with cabergoline or other dopamine agonists. Using two dopamine agonists simultaneously is redundant and significantly increases the risk of excessive dopaminergic stimulation, leading to severe nausea, orthostatic hypotension, impulse control disorders, and potential psychiatric effects. Choose one dopamine agonist and use it at an appropriate dose.

avoid

What to Expect

Day 1-3 (Titration Phase)

Begin at the starting dose of 0.125mg at bedtime. Nausea is common during the first few days and is the most frequently reported side effect. Drowsiness and mild dizziness may also occur. Prolactin suppression is minimal at this low initiation dose.

Day 4-7

If the starting dose is tolerated, increase to 0.25mg at bedtime. Initial nausea typically begins to subside as tolerance develops. Prolactin levels start to decline measurably. Some users may notice mild improvements in libido if prolactin was elevated.

Week 1-2

At 0.25-0.5mg daily, prolactin suppression becomes clinically meaningful. Sexual function improvements are noticeable in users who had prolactin-related dysfunction. Gastrointestinal side effects generally resolve. Drowsiness at bedtime is common but often considered beneficial for sleep.

Week 2-4+

Ongoing prolactin management at the maintenance dose. Steady-state plasma levels are achieved within 2-3 days of a stable dose due to the shorter half-life. Prolactin should be well controlled on bloodwork. Monitor for impulse control issues, particularly at higher doses or with prolonged use.

Side Effects & Safety

Common Side Effects

Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)

Stop Signs - Discontinue if:

Emergence of compulsive or impulsive behaviors (gambling, spending, hypersexuality, binge eating)
Hallucinations, paranoia, or other psychiatric symptoms
Episodes of falling asleep without warning during daily activities
Severe persistent nausea or vomiting that does not resolve with continued use
Severe dizziness or syncope (fainting)

Contraindications

Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism

Quality Checklist

Good Signs

White to off-white tablets of uniform size and appearance
Third-party certificate of analysis (COA) confirming identity and purity
Professional packaging with batch number, expiration date, and proper labeling
Sourced from a licensed pharmacy or reputable research supplier
Available in multiple strengths (0.125mg, 0.25mg, 0.5mg, 1mg) for proper titration

Warning Signs

No COA or third-party testing available
Tablets are inconsistent in size, color, or weight
Product labeled generically without specific compound identification
Packaging lacks batch number or expiration date

Bad Signs

Discolored, crumbling, or visibly degraded tablets
Unusual chemical odor or taste
No labeling, batch information, or expiration date
Sourced from unverified vendors with no quality documentation

References

Pramipexole, a new dopamine agonist, for the treatment of Parkinson's disease: efficacy and safety in early and advanced disease

Shannon KM, Bennett JP Jr, Friedman JH

Neurology (1997)

Demonstrated pramipexole's efficacy in treating Parkinson's disease symptoms across early and advanced stages. Established the safety and tolerability profile including common side effects of nausea, dizziness, and somnolence, and confirmed the drug's dopamine D3-preferring receptor binding profile.
Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial

Parkinson Study Group

JAMA (2000)

Landmark randomized trial of 301 patients comparing pramipexole to levodopa as initial Parkinson's therapy. Pramipexole showed fewer motor complications than levodopa over the study period and confirmed the drug's pharmacokinetic profile including its approximately 8-hour half-life and renal elimination pathway.
Impulse control disorders in Parkinson's disease: a cross-sectional study of 3090 patients

Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE

Archives of Neurology (2010)

Large cross-sectional study identifying dopamine agonists, including pramipexole, as a significant risk factor for impulse control disorders (ICDs) in Parkinson's patients. Found ICD prevalence of 13.6% in patients on dopamine agonists versus 7.2% in those not taking them. Identified pramipexole's D3 receptor preference as a potential contributing factor.
Pramipexole in restless legs syndrome: an extended-release, double-blind, randomized, placebo-controlled dose-finding study

Hogl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W

Sleep Medicine (2010)

Randomized placebo-controlled trial establishing pramipexole's dose-response relationship for restless legs syndrome. Confirmed efficacy at doses of 0.125-0.75mg daily and established the dose-titration protocol starting at 0.125mg with gradual upward adjustment to minimize adverse effects.
Effects of dopamine agonist pramipexole on prolactin secretion in healthy male volunteers

Schilling JC, Adamus WS, Palluk R

British Journal of Clinical Pharmacology (1992)

Early pharmacological study in healthy male volunteers demonstrating pramipexole's dose-dependent suppression of serum prolactin levels. Confirmed pramipexole's dopamine agonist activity at the pituitary level and characterized its prolactin-lowering potency, onset of action, and duration of effect relative to dose.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.